WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage ...

According to Bryan Johnson, the new food pyramid is beneficial for children but requires a few changes to be as helpful for ...

Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...

Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...

Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan ...

Building on their existing collaboration, the companies have signed a new agreement to focus on lead optimization of drug candidates identified by Variational AI’s Enki™ generative AI platform and ...

Diabetes is an ongoing medical condition that affects millions of people across the globe. Blood sugar needs to be controlled ...

A new tool provided a validated tumor recurrence and survival risk score for patients with lymph node-negative PanNETs.

Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment.

Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global ...